Explore Stanford technologies available for licensing:

Researchers in the Mark Kay group have identified a method to increase the rates of AAV vector-mediated HR (AAV-HR) in mammalian cells, increasing the efficiency of gene targeting rate

Background

Researchers at Stanford and the Chan Zuckerberg Biohub have discovered a Cas9 protein variant from Ignavibacterium that is thermostable at elevated temperatures.

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an efficacious therapy for patients with life-threatening leukemias, but its use has been hindered by the limited availability of donors with matching HLA. Graft manipulation by removing ??

Stanford researchers have discovered a method (Triplesect) to express molecular payloads using three-recombinase-dependent viral expression.

Researchers in Prof. Michael Lin's laboratory have developed a viral-based cancer therapy platform that could be used for targeting treatment to cancer cells with aberrant signaling in EGFR or HER2 pathways.

Researchers in Prof. Stephen Quake's laboratory have developed a CRISPER-Cas-based targeted endonuclease system designed to treat latent viral infections by attacking the viral genome.

Researchers at Stanford have shown that two CRISPR-Cas nucleases, Cas9 and Cpf1, can be programmed to produce efficient RNA-guided nickases.

Researchers at Stanford and their colleagues have developed a method to detect off-target mutations caused by gene editing tools.

Researchers at Stanford have developed methods of using CRISPR/Cas9-mediated genome editing to treat patients with EGFR-mutant non-small-cell lung cancer (NSCLC). Approximately 85% of lung cancers are NSCLC.

Researchers in the Stanford Genome Technology Center have developed a robust, high-throughput, high-efficiency functional genomics platform to generate precisely edited genome variant libraries and then readily isolate and identify thousands of individual strains en masse

Researchers at Stanford and their collaborators have developed a targeted, reversible method to manipulate chromatin structure.

Researchers at Stanford have developed methods to overcome the limited packaging capacity of adeno-associated virus (AAV) vectors and enable their use in integration of large transgenes.

Researchers in Prof. Monte Winslow's laboratory have developed two viable, fertile transgenic mouse strains that enable rapid, simple generation of loss-of-function models with CRISPR/Cas9 mediated genome editing in vivo or ex vivo.

Researchers in Prof. Mark Kay's laboratory have developed recombinant adeno-associated viral (AAV) capsid proteins that transduce human primary hepatocytes at high efficiency in vitro and in vivo.